The Europe T-Cell therapy Market would witness market growth of 17.2% CAGR during the forecast period (2023-2030).
The expansion of the market is also fueled by increased research studies and clinical trials, as well as private and public investments in advancing cell therapy technology. Additionally, the market is known for its constant evolution and expansion, primarily supported by ongoing research and development initiatives. Scientists and researchers are constantly researching new methods, tools, and therapeutic targets in the growing field of T-cell therapy to boost its efficacy and widen its uses. Additionally, immunotherapy has quickly evolved into what some refer to as the "fifth pillar" of cancer therapy over the past ten years. That's because immune system-stimulating medications have demonstrated the capacity to reduce and even eliminate tumors in some patients with advanced cancer.
According to the National Cancer Institute, the Food and Drug Administration (FDA) has given approval to six CAR T-cell treatments since 2017. All of them have received approval for treating blood malignancies, such as lymphomas, several varieties of leukemia, and multiple myeloma. The rising prevalence of such malignances has significantly propelled the R&D for developing novel therapies.
According to Myeloma Patients Europe, a pan-European organization, myeloma was identified in around 40,000 people in Europe in the year 2015, and it is anticipated that this number will nearly quadruple to 46,000 by the year 2025. The need for cutting-edge treatments has increased since multiple myeloma prevalence has been increasing in Germany. Due to significant advancements in the development of innovative multiple myeloma treatments, the market is growing. The favorable reimbursement policies offered by the German healthcare system for cancer treatments contribute to the market's rise. Hence, because of all these elements, the region presents lucrative growth prospects for expanding the market throughout the forecast period.
The Germany market dominated the Europe T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $613 million by 2030. The UK market is anticipated to grow at a CAGR of 16.2% during (2023 - 2030). Additionally, The France market would exhibit a CAGR of 18.1% during (2023 - 2030).
Based on End User, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide T-Cell therapy Market is Projected to reach USD 9.2 Billion by 2030, at a CAGR of 17.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By End User
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe T-Cell therapy Market, by End User
1.4.2 Europe T-Cell therapy Market, by Indication
1.4.3 Europe T-Cell therapy Market, by Therapy Type
1.4.4 Europe T-Cell therapy Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Geographical Expansions
3.2.5 Trials and Approvals
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
Chapter 4. Europe T-Cell therapy Market by End User
4.1 Europe Hospitals Market by Country
4.2 Europe Cancer Treatment Centers Market by Country
Chapter 5. Europe T-Cell therapy Market by Indication
5.1 Europe Lymphoma Market by Country
5.2 Europe Acute Lymphocytic Leukemia Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe T-Cell therapy Market by Therapy Type
6.1 Europe CAR T-Cell Therapy Market by Country
6.2 Europe T-Cell therapy Market by CAR T-Cell Therapy Type
6.2.1 Europe Axicabtagene Ciloleucel Market by Country
6.2.2 Europe Tisagenlecleucel Market by Country
6.2.3 Europe Brexucabtagene Autoleucel Market by Country
6.2.4 Europe Others Market by Country
6.3 Europe T-Cell Receptor (TCR)-Based Market by Country
Chapter 7. Europe T-Cell therapy Market by Country
7.1 Germany T-Cell therapy Market
7.1.1 Germany T-Cell therapy Market by End User
7.1.2 Germany T-Cell therapy Market by Indication
7.1.3 Germany T-Cell therapy Market by Therapy Type
7.1.3.1 Germany T-Cell therapy Market by CAR T-Cell Therapy Type
7.2 UK T-Cell therapy Market
7.2.1 UK T-Cell therapy Market by End User
7.2.2 UK T-Cell therapy Market by Indication
7.2.3 UK T-Cell therapy Market by Therapy Type
7.2.3.1 UK T-Cell therapy Market by CAR T-Cell Therapy Type
7.3 France T-Cell therapy Market
7.3.1 France T-Cell therapy Market by End User
7.3.2 France T-Cell therapy Market by Indication
7.3.3 France T-Cell therapy Market by Therapy Type
7.3.3.1 France T-Cell therapy Market by CAR T-Cell Therapy Type
7.4 Russia T-Cell therapy Market
7.4.1 Russia T-Cell therapy Market by End User
7.4.2 Russia T-Cell therapy Market by Indication
7.4.3 Russia T-Cell therapy Market by Therapy Type
7.4.3.1 Russia T-Cell therapy Market by CAR T-Cell Therapy Type
7.5 Spain T-Cell therapy Market
7.5.1 Spain T-Cell therapy Market by End User
7.5.2 Spain T-Cell therapy Market by Indication
7.5.3 Spain T-Cell therapy Market by Therapy Type
7.5.3.1 Spain T-Cell therapy Market by CAR T-Cell Therapy Type
7.6 Italy T-Cell therapy Market
7.6.1 Italy T-Cell therapy Market by End User
7.6.2 Italy T-Cell therapy Market by Indication
7.6.3 Italy T-Cell therapy Market by Therapy Type
7.6.3.1 Italy T-Cell therapy Market by CAR T-Cell Therapy Type
7.7 Rest of Europe T-Cell therapy Market
7.7.1 Rest of Europe T-Cell therapy Market by End User
7.7.2 Rest of Europe T-Cell therapy Market by Indication
7.7.3 Rest of Europe T-Cell therapy Market by Therapy Type
7.7.3.1 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type
Chapter 8. Company Profiles
8.1 Merck KGaA
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Johnson & Johnson
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental &Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.5.2 Acquisition and Mergers:
8.3 AbbVie, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Gilead Sciences, Inc.
8.4.1 Company overview
8.4.2 Financial Analysis
8.4.3 Research & Development Expenses
8.4.4 Recent strategies and developments:
8.4.4.1 Partnerships, Collaborations, and Agreements:
8.4.4.2 Acquisition and Mergers:
8.4.4.3 Trials and Approvals:
8.5 Amgen, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Acquisition and Mergers:
8.6 Novartis AG
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Product Launches and Product Expansions:
8.6.5.2 Acquisition and Mergers:
8.6.5.3 Trials and Approvals:
8.7 Sorrento Therapeutics, Inc.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.7.5.2 Trials and Approvals:
8.8 Bristol Myers Squibb Company
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.5.2 Acquisition and Mergers:
8.8.5.3 Geographical Expansions:
8.8.5.4 Trials and Approvals:
8.9 Pfizer, Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Regional & Segmental Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.10. Immunocore Holdings plc
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Research & Development Expenses
8.10.4 Recent strategies and developments:
8.10.4.1 Partnerships, Collaborations, and Agreements:
8.10.4.2 Trials and Approvals:
TABLE 1 Europe T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 2 Europe T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– T-Cell therapy Market
TABLE 4 Product Launches And Product Expansions– T-Cell therapy Market
TABLE 5 Acquisition and Mergers– T-Cell therapy Market
TABLE 6 Geographical Expansions – T-Cell therapy Market
TABLE 7 Trials and Approvals – T-Cell therapy Market
TABLE 8 Europe T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 9 Europe T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 10 Europe Hospitals Market by Country, 2019 - 2022, USD Million
TABLE 11 Europe Hospitals Market by Country, 2023 - 2030, USD Million
TABLE 12 Europe Cancer Treatment Centers Market by Country, 2019 - 2022, USD Million
TABLE 13 Europe Cancer Treatment Centers Market by Country, 2023 - 2030, USD Million
TABLE 14 Europe T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 15 Europe T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 16 Europe Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 17 Europe Lymphoma Market by Country, 2023 - 2030, USD Million
TABLE 18 Europe Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 19 Europe Acute Lymphocytic Leukemia Market by Country, 2023 - 2030, USD Million
TABLE 20 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 21 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 22 Europe T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 23 Europe T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 24 Europe CAR T-Cell Therapy Market by Country, 2019 - 2022, USD Million
TABLE 25 Europe CAR T-Cell Therapy Market by Country, 2023 - 2030, USD Million
TABLE 26 Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 27 Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 28 Europe Axicabtagene Ciloleucel Market by Country, 2019 - 2022, USD Million
TABLE 29 Europe Axicabtagene Ciloleucel Market by Country, 2023 - 2030, USD Million
TABLE 30 Europe Tisagenlecleucel Market by Country, 2019 - 2022, USD Million
TABLE 31 Europe Tisagenlecleucel Market by Country, 2023 - 2030, USD Million
TABLE 32 Europe Brexucabtagene Autoleucel Market by Country, 2019 - 2022, USD Million
TABLE 33 Europe Brexucabtagene Autoleucel Market by Country, 2023 - 2030, USD Million
TABLE 34 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 35 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 36 Europe T-Cell Receptor (TCR)-Based Market by Country, 2019 - 2022, USD Million
TABLE 37 Europe T-Cell Receptor (TCR)-Based Market by Country, 2023 - 2030, USD Million
TABLE 38 Europe T-Cell therapy Market by Country, 2019 - 2022, USD Million
TABLE 39 Europe T-Cell therapy Market by Country, 2023 - 2030, USD Million
TABLE 40 Germany T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 41 Germany T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 42 Germany T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 43 Germany T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 44 Germany T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 45 Germany T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 46 Germany T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 47 Germany T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 48 Germany T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 49 Germany T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 50 UK T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 51 UK T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 52 UK T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 53 UK T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 54 UK T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 55 UK T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 56 UK T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 57 UK T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 58 UK T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 59 UK T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 60 France T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 61 France T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 62 France T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 63 France T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 64 France T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 65 France T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 66 France T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 67 France T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 68 France T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 69 France T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 70 Russia T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 71 Russia T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 72 Russia T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 73 Russia T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 74 Russia T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 75 Russia T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 76 Russia T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 77 Russia T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 78 Russia T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 79 Russia T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 80 Spain T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 81 Spain T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 82 Spain T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 83 Spain T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 84 Spain T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 85 Spain T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 86 Spain T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 87 Spain T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 88 Spain T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 89 Spain T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 90 Italy T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 91 Italy T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 92 Italy T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 93 Italy T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 94 Italy T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 95 Italy T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 96 Italy T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 97 Italy T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 98 Italy T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 99 Italy T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 100 Rest of Europe T-Cell therapy Market, 2019 - 2022, USD Million
TABLE 101 Rest of Europe T-Cell therapy Market, 2023 - 2030, USD Million
TABLE 102 Rest of Europe T-Cell therapy Market by End User, 2019 - 2022, USD Million
TABLE 103 Rest of Europe T-Cell therapy Market by End User, 2023 - 2030, USD Million
TABLE 104 Rest of Europe T-Cell therapy Market by Indication, 2019 - 2022, USD Million
TABLE 105 Rest of Europe T-Cell therapy Market by Indication, 2023 - 2030, USD Million
TABLE 106 Rest of Europe T-Cell therapy Market by Therapy Type, 2019 - 2022, USD Million
TABLE 107 Rest of Europe T-Cell therapy Market by Therapy Type, 2023 - 2030, USD Million
TABLE 108 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2019 - 2022, USD Million
TABLE 109 Rest of Europe T-Cell therapy Market by CAR T-Cell Therapy Type, 2023 - 2030, USD Million
TABLE 110 key Information – Merck KGaA
TABLE 111 Key information –Johnson & Johnson
TABLE 112 Key information – AbbVie, Inc.
TABLE 113 Key Information – Gilead Sciences, Inc.
TABLE 114 Key Information – Amgen, Inc.
TABLE 115 Key Information – Novartis AG
TABLE 116 Key Information – Sorrento Therapeutics, Inc.
TABLE 117 Key Information – Bristol Myers Squibb Company
TABLE 118 Key Information – Pfizer, Inc.
TABLE 119 Key Information – Immunocore Holdings plc
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2020, Sep – 2023, May) Leading Players
FIG 5 Europe T-Cell therapy Market share by End User, 2022
FIG 6 Europe T-Cell therapy Market share by End User, 2030
FIG 7 Europe T-Cell therapy Market by End User, 2019 - 2030, USD Million
FIG 8 Europe T-Cell therapy Market share by Indication, 2022
FIG 9 Europe T-Cell therapy Market share by Indication, 2030
FIG 10 Europe T-Cell therapy Market by Indication, 2019 - 2030, USD Million
FIG 11 Europe T-Cell therapy Market share by Therapy Type, 2022
FIG 12 Europe T-Cell therapy Market share by Therapy Type, 2030
FIG 13 Europe T-Cell therapy Market by Therapy Type, 2019 - 2030, USD Million
FIG 14 Europe T-Cell therapy Market share by Country, 2022
FIG 15 Europe T-Cell therapy Market share by Country, 2030
FIG 16 Europe T-Cell therapy Market by Country, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: Merck KGaA
FIG 18 Recent strategies and developments: Johnson & Johnson
FIG 19 SWOT analysis: Johnson & Johnson
FIG 20 Recent strategies and developments: Gilead Sciences, Inc.
FIG 21 Recent strategies and developments: Amgen, Inc.
FIG 22 Recent strategies and developments: Novartis AG
FIG 23 Recent strategies and developments: Sorrento Therapeutics, Inc.
FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
FIG 25 Recent strategies and developments: Pfizer, Inc.
FIG 26 Recent strategies and developments: Immunocore Holdings plc